Among those pathways, mitotic spindle and allograft rejection may activate the HNSCC tumorigenesis, however, MYC target v1 and oxidative phospho- rylation may suppress the trends of progression (Fig. 6B–D). The gene discussed is MYC; the disease is head and neck squamous cell carcinoma.